Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Selects ICON to Validate PROs | Contract Pharma

What are you searching for?

Sign in
Breaking News

FDA Selects ICON to Validate PROs

Will measure clinical endpoints in antibacterial drug trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ICON plc has been selected by the U.S. FDA to validate three Patient Reported Outcomes (PRO) instruments that will measure clinical endpoints in antibacterial drug trials. This is the 2nd time ICON has been selected by the FDA to create industry-standard PRO measures.
 
The endpoints to be validated are Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP) and Hospital-Acquired Bacterial Pneumonia (HABP). Currently, there are no qualified PRO instruments to assess the primary endpoints in these trials.
 
ICON in collaboration with the Biomarkers Consortium of the Foundation for the National Institutes of Health (FNIH), are creating an electronic platform to validate key PROs, allowing investigators to assess the symptoms of ABSSSI, CABP and HABP at various time points over the course of the infection and measure the effects of antibacterial drugs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics